ClinicalTrials.gg
CompletedNCT03156439Updated Jan 18, 2018

Bioavailability, Safety, and Tolerability of BIS-001 ER

A Phase 1 interventional study of BIS-001 ER in Epilepsy, Complex Partial, sponsored by Supernus Pharmaceuticals, Inc.. Completed at 1 site in Australia. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-01-18.

Sponsored by Supernus Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study investigates the safety, tolerability, and pharmacokinetics of BIS-001 ER in healthy volunteers. Subjects will be dosed twice daily, with a dose escalation occurring every 2-3 days until a maximum dose of 5mg per day is reached.

02

Conditions studied

  • Epilepsy, Complex Partial
03

In context

Lead sponsor

Supernus Pharmaceuticals, Inc. is the lead sponsor of 64 studies on the registry; 6 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 26 (81%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Speak English with sufficient proficiency to read and comprehend the document, and to communicate with study staff.
  2. Be able to consent to participate by signing the Informed Consent document after a full explanation of the nature and purpose of this study.
  3. Have signed the Informed Consent before any study-specific procedures are performed
  4. Be males or females between 18 - 45 years of age.
  5. Have a negative urinary pregnancy test upon admission to the site on Day 1
  6. Be in good general health in the judgment of the Principal Investigator based upon medical history, physical examination, standard 12-lead (ECG), and clinical laboratory evaluations obtained within the two weeks prior to enrollment.
  7. Be able to comply with all study-specified procedures.
  8. Weight between 40 and 100 kg

Exclusion criteria

Exclusion Criteria:

  1. Has taken Huperzine A.
  2. Is planning to become pregnant or impregnate spouse, not using an acceptable method of (defined as use of double-barrier birth control methods, use of oral contraceptives, or surgical sterilization), pregnant or nursing
  3. Has a pre-existing medical condition (including an existing progressive or degenerative neurological disorder) or takes medications that, in the Principal Investigator's opinion, could interfere with the subject's suitability for participation in the study.
  4. Has a history or evidence of significant psychiatric disturbance or illness, including alcohol or drug abuse within the past 2 years, or symptoms of psychosis (hallucinations, delusions) in the last 5 years.
  5. Has had any clinical laboratory abnormalities within the past two months, prior to screening, considered of clinical significance by the Principal Investigator
  6. Is on concomitant therapy with non-anti-epileptic drugs (AEDs) that are cholinergic.
  7. Has participated in any clinical drug or device study within four weeks prior to study entry.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    BIS-001 ER

    The subjects will be dosed twice daily (BID); in an on-site setting at dose initiation and at times of dose escalation to evaluate safety, and for specimen collection for routine laboratory and pharmacokinetic analysis. Subjects will be discharged and compliance of BID dosing will be monitored via twice daily phone calls by site staff. The initial dose will be 0.5mg BID with a dose escalation every 2-3 days until a maximum tolerated dose is observed or a maximum of 2.5mg BID dose is obtained.

    Drug: BIS-001 ER

Interventions

  • BIS-001 ER is an extended release formulation of the nutritional supplement Huperzine A.

    Also known as: Huperzine A

06

What researchers measure

Primary outcomes

  1. Maximum serum concentration; Cmax

    Bioavailability/Pharmacokinetic Assessments

    Time frame: 16 Weeks

  2. Area under the curve; AUC

    Bioavailability/Pharmacokinetic Assessments

    Time frame: 16 Weeks

  3. Time of maximum serum concentration; Tmax

    Bioavailability/Pharmacokinetic Assessments

    Time frame: 16 Weeks

  4. Half-life; t1/2

    Bioavailability/Pharmacokinetic Assessments

    Time frame: 16 Weeks

  5. Terminal elimination

    Bioavailability/Pharmacokinetic Assessments

    Time frame: 16 Weeks

  6. Clearance

    Bioavailability/Pharmacokinetic Assessments

    Time frame: 16 Weeks

  7. Volume of distribution

    Bioavailability/Pharmacokinetic Assessments

    Time frame: 16 Weeks

  8. Mean residence time

    Bioavailability/Pharmacokinetic Assessments

    Time frame: 16 Weeks

Secondary outcomes

  1. Safety and Tolerability Assessments - Adverse Events

    Adverse events will be defined, documented, evaluated (mild/moderate/severe/life threatening; serious/non-serious; expected/unexpected; causally related to study drug or not) and reported according to all applicable institutional and governmental requirements and guidance.

    Time frame: 16 Weeks

  2. Safety and Tolerability Assessments - Vital Signs

    Vital signs (e.g. blood pressure) will be monitored through the first 8 hrs after drug administration, as well as at Baseline and pre-dose.

    Time frame: 16 Weeks

  3. Safety and Tolerability Assessments - Neurological Evaluation

    A standard neurological examination will be performed according to the study-specific timeline. Clinically significant new or worsened abnormalities as compared to baseline findings will have to be reported as AEs.

    Time frame: 16 Weeks

  4. Safety and Tolerability Assessments - Physical Evaluation

    A standard physical examination will be performed according to the study-specific timeline. Clinically significant new or worsened abnormalities as compared to baseline findings will have to be reported as AEs.

    Time frame: 16 Weeks

  5. Safety and Tolerability Assessments - ECG Evaluation

    A standard 12-lead ECG in a supine position after a 5-minute rest will be performed according to the study-specific timeline. The Investigator will determine whether the results of the ECG are normal or abnormal and assess the clinical significance of any abnormality. ECG tracings will be reviewed by a cardiologist if required.

    Time frame: 16 Weeks

  6. Safety and Tolerability Assessments - Clinical Laboratory Studies: Hematology

    Laboratory assessments will be conducted using standard methods.

    Time frame: 16 Weeks

  7. Safety and Tolerability Assessments - Clinical Laboratory Studies: Biochemistry

    Laboratory assessments will be conducted using standard methods.

    Time frame: 16 Weeks

  8. Safety and Tolerability Assessments - Clinical Laboratory Studies: Urinalysis

    Laboratory assessments will be conducted using standard methods.

    Time frame: 16 Weeks

07

Study locations

1 site
  • The Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2017 to primary completion in Sep 2017, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2017
First posted
May 17, 2017
StartActual
May 22, 2017
Primary completionActual
Sep 30, 2017
CompletionActual
Sep 30, 2017
Last update
Jan 18, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03156439
Collaborators
Melbourne Health
Responsible party
Sponsor
First posted
May 17, 2017
Start date
May 22, 2017
Primary completion
Sep 30, 2017
Completion
Sep 30, 2017
Last update
Jan 18, 2018

Study contacts

Stephen D Collins
study chair · President and CEO

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Huperzine A

Start the discussion